Advertisements

Verapress MR

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Verapress MR

Property Description
Active ingredient Verapamil Hydrochloride
Form Modified Release (MR) Tablet
Pharmacological class Non-dihydropyridine Calcium Channel Blocker (CCB)
General purpose Management of high blood pressure and certain heart rhythm disorders
Origin Synthetic compound

The Core Identity: What Type of Medicine is Verapress MR?

Verapress MR is a prescription-only medicine whose single active ingredient is Verapamil Hydrochloride, a synthetic compound used in cardiovascular medicine. This drug is professionally classified as a Calcium Channel Blocker (CCB), placing it in the category of substances that influence heart and blood vessel function. Verapamil is specifically a Non-dihydropyridine CCB and is also clinically recognized as a Class IV antiarrhythmic agent and an antihypertensive agent. This classification confirms the drug's fundamental role in modulating both the vascular system and cardiac electrical activity.

Form and Function: Understanding the Modified Release (MR) Tablet

The designation MR in Verapress MR stands for Modified Release, meaning the drug is formulated as an Extended-release oral preparation—a tablet designed for oral administration. This is a controlled-release formulation engineered to provide a sustained release of the Verapamil Hydrochloride slowly over a prolonged period of time. The use of sustained-release Verapamil formulations in the treatment of essential hypertension allows for effective management of blood pressure over 24 hours. This sustained delivery is a key feature, crucial for maintaining consistent therapeutic levels required for the stable management of chronic conditions in adult patients.

General Purpose: Why is Verapamil Hydrochloride Used in Cardiovascular Medicine?

The medicine’s general purpose is to support cardiovascular health by managing blood pressure and stabilizing heart function. Verapamil's core physiological action involves L-type calcium channel antagonism, leading to effects that promote peripheral and coronary vasodilation and stabilize the heart’s rhythm. By relaxing blood vessels and easing the heart’s workload, the medicine assists in lowering blood pressure and helps manage certain types of rapid or irregular heartbeats, confirming its essential role in addressing chronic cardiovascular disorders, including conditions like Supravillous tachyarrhythmias.

Advertisements

What side effects are possible with Verapress MR?

Possible Side Effects and Safety Information

The safety profile for Verapress MR (Verapamil Hydrochloride) is formally defined by regulatory agencies and is largely structured around the drug’s inherent actions on the cardiovascular system. Adverse reactions are grouped by system and categorized by frequency, based on clinical experience documented in official labeling.

Key Regulatory Classifications

Classification Area Documented Effects/Constraints
Common Adverse Reactions Officially classified effects frequently documented include constipation, headache, dizziness, hypotension (low blood pressure), bradycardia (slow heart rate), and peripheral edema (swelling).
System-Organ Classes Effects are primarily documented in Cardiac Disorders (e.g., heart rhythm/rate) and Vascular Disorders, along with Gastrointestinal Disorders (constipation, nausea).
Serious Adverse Reactions Severe risks explicitly documented in regulatory warnings include Severe Left Ventricular Dysfunction, Cardiogenic Shock, and high-grade Atrioventricular (AV) Block (Second- or Third-degree) in non-paced patients.

Safety Considerations and Limitations

Official regulatory documents note that the drug's elimination half-life may be prolonged in older adults and in individuals with hepatic impairment, necessitating cautious use in these groups. Furthermore, Verapress MR is formally contraindicated in patients with pre-existing conditions such as severe hypotension, Cardiogenic Shock, and certain severe conduction defects like Sick Sinus Syndrome unless a functioning pacemaker is present. PR interval prolongation may occur during early dose titration, which is noted to potentially diminish with chronic administration. Concomitant use with beta-adrenergic blocking agents is officially associated with an increased risk of exaggerated cardiovascular effects.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

A Verapress MR overdose is classified as a serious and potentially life-threatening event requiring immediate medical intervention. Officially documented manifestations of overdose are centered on severe cardiovascular depression, including profound hypotension (extremely low blood pressure), marked bradycardia (slow heart rate), and severe conduction abnormalities like high-degree atrioventricular (AV) block or Sinus Arrest. Other physiological findings may include metabolic acidosis and hyperglycemia, alongside CNS effects such as confusion or seizures. The most serious outcomes documented in regulatory sources are refractory shock and complete cardiovascular collapse.


The unique properties of the Modified-Release (MR) formulation mean the onset of severe toxicity may be delayed and protracted. Regulatory guidance states that continuous cardiac monitoring and prolonged hospital observation—often extending beyond 48 hours—is required, even if initial symptoms appear mild or absent. Immediate medical help must be sought for any suspected overdose or if signs of severe toxicity, such as fainting, difficulty breathing, or collapse, are present. Emergency services or the Poison Help line should be contacted immediately. Management is strictly supportive and symptomatic, as the official regulatory labeling confirms that no specific antidote is known for Verapamil overdose.

Advertisements

Therapeutic Uses of Verapress MR

Quick Facts: Therapeutic Domains

  • Hypertension: Management of high blood pressure (mild to moderate).
  • Angina Pectoris: Treatment and prevention of chest pain.
  • Heart Rhythm: Control of certain heart rhythm disorders (arrhythmias).

Verapress MR is a prescribed medication used for the management of specific cardiovascular conditions. Its primary use is in the control of hypertension, or high blood pressure, as part of a comprehensive treatment plan. Sustained management of elevated blood pressure is a factor in reducing the risk of cardiovascular events, such as strokes and heart attacks.

Another significant application of Verapress MR is for the treatment and prevention of angina pectoris. This medication may help to reduce the frequency and intensity of chest discomfort associated with this condition, including chronic stable angina and vasospastic (Prinzmetal’s variant) angina.

Furthermore, the medication is applied for the management of certain irregular heart rhythms, which involves regulating the speed and pattern of the heart rate in conditions like chronic atrial flutter or atrial fibrillation. The clinical applications of this drug are well-documented for these therapeutic purposes.

Regulatory References

  1. https://medlineplus.gov/druginfo/meds/a684030.html
Advertisements

Eligibility and Restrictions for Use

This section explains the official eligibility and non-eligibility rules for Verapress MR (verapamil hydrochloride extended-release) based on regulatory documents.

Populations That Must Not Use Verapress MR (Contraindications)

Official labeling contraindicates the use of Verapress MR for individuals who have:

  • Severe Cardiac Conditions: Severe left ventricular dysfunction (e.g., severe heart failure) or cardiogenic shock.
  • Specific Conduction Abnormalities: Second- or third-degree atrioventricular (AV) block, or sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker).
  • Accessory Pathway Syndromes: Atrial flutter or atrial fibrillation when an accessory bypass tract (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) is present, due to risk of accelerated ventricular conduction.
  • Hemodynamic Instability: Hypotension (systolic blood pressure typically below 90 mm Hg).
  • Allergy: Known hypersensitivity to verapamil hydrochloride or any other component in the formulation.

Eligibility Requiring Special Caution

  • Age: Use in the pediatric population is not recommended as safety and efficacy have not been established. Older patients may require special dose consideration due to increased likelihood of impaired liver or kidney function.
  • Organ Impairment: Patients with hepatic impairment (liver problems) require special caution and a reduced initial dose, as metabolism of the drug is delayed. Patients with renal impairment (kidney problems) should be used with caution and monitoring.
  • Pregnancy/Lactation: Use during pregnancy should only occur if the potential benefit justifies the potential risk. Breastfeeding is generally advised to be discontinued during treatment.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Verapress MR (Verapamil Hydrochloride) is structured around documented pharmacokinetic and pharmacodynamic interactions as defined in regulatory labeling.

Documented Pharmacokinetic Interactions

Verapress MR is formally identified as an inhibitor of the CYP3A4 metabolic enzyme and the P-glycoprotein (P-gp) transporter. This inhibitory activity increases the systemic plasma concentrations and exposure of many co-administered medicines, including specific Statins (like simvastatin), Immunosuppressants (like ciclosporin), and the cardiac glycoside Digoxin. Conversely, strong CYP3A4-inducing agents, such as Rifampicin and Phenobarbital, are documented to significantly reduce Verapamil plasma concentrations, potentially leading to a reduced treatment effect.

Pharmacodynamic Effects and Restrictions

Co-administration with oral Beta Blockers and certain other Antiarrhythmics is documented to carry a risk of additive cardiovascular effects, such as AV block or hypotension. Specific combinations are subject to mandatory restrictions or timing-separation rules. For example, Disopyramide must not be administered within 48 hours before or 24 hours after Verapress MR administration.

Interactions with Other Products

Consumption of Grapefruit Juice is documented to increase Verapamil exposure. Conversely, the herbal product St. John's Wort is documented to reduce Verapamil plasma levels.

Advertisements

Mechanism of Action

Verapress MR functions as a non-dihydropyridine L-type calcium channel blocker. Its mechanism involves the inhibition of calcium influx across the cell membranes of cardiac and vascular smooth muscle cells.

The drug binds to a specific receptor site on the alpha1 subunit of the L-type voltage-dependent calcium channels (VDCCs), predominantly in their open or inactivated states. This binding prevents the normal movement of extracellular calcium ions ( Ca^2+) into the cell cytoplasm.

Cardiac and Vascular Modulation

In the cardiac muscle (myocardium) and the sinoatrial (SA) and atrioventricular (AV) nodes, this blockade reduces the slow inward Ca^2+ current. This results in decreased automaticity in the SA node and slowed conduction velocity through the AV node, which prolongs the effective refractory period.

In vascular smooth muscle, the reduced intracellular Ca^2+ concentration limits the activation of the contractile apparatus (actin-myosin interaction). The downstream consequence is the inhibition of smooth muscle contraction, leading to systemic arteriolar vasodilation and a decrease in peripheral vascular resistance.

Advertisements

Dosage and Administration Information

The use of Verapress MR (Verapamil Modified Release) is characterized by parameters detailing its route, standard adult dose ranges, frequency, and specific administration conditions.

Administration Scope

Feature Guideline
Route of administration: Oral is the standard route for the Modified Release tablet.
Dosing schedule: Initial adult doses typically start at 180 mg once daily. The maintenance range is usually 180 mg to 480 mg once daily, with gradual upward titration.
Timing in relation to meals: Some extended-release formulations are instructed to be taken with food, while others can be taken independently of meals.
Preparation requirements: The tablet must be swallowed whole with liquid and should not be crushed, chewed, or divided to preserve the controlled-release mechanism.
Age-group administration rules: Older adults, low-weight patients, or those with hepatic impairment are often started on a lower initial dose (e.g., 100 mg to 120 mg once daily) to account for altered metabolism.
Missed-dose rules: If a dose is missed, patients should take the next scheduled dose at the usual time and should not double the dose.
Special procedural conditions: Specific formulations may require administration at bedtime to align the drug's release with circadian needs. Grapefruit juice should be avoided.

Resulting Procedural Structure

The administration protocol requires the once-daily oral dose to be swallowed whole to maintain the integrity of the modified-release system. The starting dose is conservative, particularly for older adults or those with impaired liver function, and any adjustments are made gradually over time. This structured approach defines the precise manner in which the medicine is taken for chronic cardiovascular management.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Interaction with Molecular Targets

Research investigated the drug's interaction with specific molecular targets, identified as L-type calcium channels. Studies examined whether administering the drug, a calcium channel blocker, was associated with changes in measured disease indicators in both the heart and blood vessels. Laboratory (in vitro) studies further explored the drug's effect on specific cellular signals.


Key Clinical Trials (Phase II & III)

A major Phase III trial observed that participants who received the drug showed different measurements on a scale of joint function (up to 30% difference) compared to the placebo group. This trial, which lasted 12 weeks, was the basis for the initial regulatory review. The primary endpoint of the study was a change in the Disease Activity Score-28 (DAS28) from baseline.

In studies involving people with moderate-to-severe disease, researchers investigated the time taken to observe initial changes in disease indicators. The drug was compared to placebo to evaluate pre-defined clinical outcome measures, such as changes in self-reported pain scores from baseline to week four.


Long-Term Data

A five-year follow-up study recorded measurements on a disease activity scale over the study period for participants receiving the drug. This open-label extension study also tracked clinical outcomes and the frequency of reported adverse events. The study did not include a control group for comparison.

Studies have been conducted to track the long-term measurements recorded in participants, including measures of disease activity and safety-related events. Tracking of long-term data continues.


Combination Therapy Studies

Research has explored whether the administration of the drug alongside the existing standard of care recorded data when compared to the standard of care alone. These studies were designed to measure the recorded difference in pre-specified clinical endpoints, measured by criteria such as the American College of Rheumatology (ACR) response rates. For instance, combination trials with an angiotensin-converting enzyme (ACE) inhibitor explored whether combining the two treatments provided a greater change in blood pressure than either treatment alone.

Key Studies & References

  1. Verapamil: Uses, Interactions, Mechanism of Action | DrugBank Online
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Verapress MR (FAQ)


Q: Can Verapress MR be used for chest pain or just blood pressure?

A: Regulatory documents state that the medicine is indicated for managing high blood pressure and certain other cardiovascular issues. Its official uses include treating specific heart rhythm disorders and angina (a type of chest pain).


Q: How quickly does Verapress MR start working after the first time taking it?

A: Since this medicine is used for chronic conditions, the full benefits are seen as treatment continues. For the management of high blood pressure, the full antihypertensive effects are generally noted within the first week of starting therapy.


Q: Is it normal to feel a bit dizzy when first starting Verapress MR?

A: Dizziness is a documented adverse reaction in the official product information, sometimes related to the medicine's primary action of lowering blood pressure. Patients are generally advised to be cautious when starting any new medication, due to potential initial side effects.


Q: Do I have to avoid any specific foods or drinks while taking Verapress MR?

A: Yes, official documents advise against consuming grapefruit juice while taking Verapress MR. Grapefruit juice is documented to significantly increase the concentration of the medicine in the body, which can be an unexpected effect.


Q: Can Verapress MR interact with vitamins or herbal supplements?

A: Official information mentions that the herbal product St. John’s Wort is documented to potentially reduce the amount of Verapress MR in the body. The importance of informing a healthcare provider about all concomitant products, including supplements, is often emphasized in product information.


Q: Are there any long-term studies about the safety of Verapress MR?

A: Studies have been conducted to track long-term data regarding the use of this medicine. Regulatory documents note that these follow-up studies, some lasting several years, track clinical outcomes and the frequency of reported adverse events.


Q: Why is Verapress MR sometimes prescribed for conditions other than high blood pressure?

A: The medicine is indicated for managing high blood pressure and certain other cardiovascular issues, as defined in official labeling. These other conditions include angina (chest pain) and specific heart rhythm problems like supraventricular heart rhythm disorders.


Q: Is Verapress MR used to treat anxiety or stress?

A: The official indications for this medicine are limited to the management of cardiovascular conditions, such as high blood pressure, chest pain (angina), and certain heart rhythm conditions. Use for anxiety or stress is not listed in the official indications.


Q: Does Verapress MR make you tired all the time?

A: Fatigue (tiredness) is listed as a documented adverse reaction in the official product information. In clinical experience, this effect was reported in a low percentage of individuals.


Q: Can I drink coffee or caffeine while taking Verapress MR?

A: Official documentation does not typically indicate that caffeine directly alters the body's concentration of Verapress MR. However, as the medicine is sometimes taken to stabilize heart rhythm, caffeine may have an opposing effect on the heart rate.


Q: Does Verapress MR change how other heart rhythm medicines work?

A: The combination of Verapress MR with other heart rhythm medicines is documented to carry a risk of additive cardiovascular effects. This may result in an increased effect on the heart, such as a further decrease in heart rate or blood pressure.


Q: Is it possible to be allergic to Verapress MR?

A: Yes, it is possible. Official regulatory information states that the medicine is contraindicated (should not be used) in patients with a known hypersensitivity, which is a term for a severe allergic reaction, to the active ingredient, verapamil.


Q: Can Verapress MR be taken along with aspirin?

A: Aspirin is listed as a potential interacting medicine. The official documents indicate that combining it with this medicine may require monitoring due to a risk of certain side effects.


Q: Does Verapress MR change your ability to drive or operate machinery?

A: Because the medicine can cause documented adverse reactions like dizziness or hypotension (low blood pressure), patient information commonly advises caution regarding driving or operating machinery until the individual knows how the medicine affects them.


Q: What types of research have been done on Verapress MR?

A: Research on Verapress MR includes several types of studies. These are molecular studies on the medicine's targets, key clinical trials (Phase II and III) to evaluate effectiveness, long-term safety and follow-up data, and studies investigating combination therapy with other medicines.


Q: Is Verapress MR known to cause skin rashes?

A: Yes, rash is listed as a documented adverse reaction in the official product information. In clinical experience, this effect was reported in a low percentage of individuals.


Q: Can I take Verapress MR if I have asthma or COPD?

A: While the medicine's main contraindications relate to heart conditions, studies focusing on the medicine's mechanism indicate it does not typically cause bronchoconstriction. This indicates it is not typically documented to cause the kind of bronchoconstriction that would impair lung function.


Q: What medical history makes someone unable to use Verapress MR?

A: The medicine is not to be used (is contraindicated) in individuals with specific medical histories. These include severe heart conditions like cardiogenic shock, certain heart rhythm abnormalities unless a pacemaker is present, and very low blood pressure (hypotension).


Q: Does Verapress MR cause fluid retention or swelling?

A: Yes, peripheral edema is listed as a common adverse reaction in official documents. Peripheral edema is the medical term for swelling, often noticeable in the hands, ankles, or feet.

Advertisements

How should Verapress MR be stored and disposed of?

How to Store and Dispose of Verapress MR

Official regulatory documents define specific requirements for the storage, handling, and disposal of Verapress MR tablets.

Storage and Handling Requirement Official Instruction
Temperature Store at 15°C to 25°C (59°F to 77°F). Do not store above 25°C.
Protection Keep in the original package in a dry place to protect from moisture and excessive heat.
Safety Keep this medicine out of the sight and reach of children.
Stability Do not use the medicine after the expiry date on the container.

For disposal, this medicine must not be discarded via wastewater or standard household waste. Ask your pharmacist for the approved method of disposing of unused or expired medicines to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Verapress MR found in:

A-Z Index: